Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Bain Capital Life Sciences Investors, LLC
Form 13F · Q2 2026

Bain Capital Life Sciences Investors, LLC

CIK 1703031Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.7B
Reported book value
21
Positions
12
Quarters on record
Top 50
Positions

Bain Capital Life Sciences Investors, LLC — holdings

Top 21 positions of 21, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1KLRA Kailera Therapeutics Inc22.6M—$498M29.6%
2HTFL Heartflow Inc8.4M−19.1%$248M14.7%
3NAMS Newamsterdam Pharma Company3.8M−47.9%$129M7.7%
4SVRA Savara Inc17.6M+0.0%$108M6.4%
5ALKS Alkermes Plc1.9M+217.7%$102M6.0%
6SLDB Solid Biosciences Inc9.8M+0.0%$98M5.8%
7PHVS Pharvaris N V2.7M+0.0%$93M5.5%
8OLEMA PHARMACEUTICALS INC Olema Pharmaceuticals Inc7.1M−5.2%$89M5.3%
9COAG Hemab Therapeutics Hldgs Inc1.6M—$61M3.6%
10CABA Cabaletta Bio Inc17.2M+78.2%$54M3.2%
11XFOR X4 Pharmaceuticals Inc8.0M+0.0%$37M2.2%
12DNTH Dianthus Therapeutics Inc362,470+0.0%$35M2.1%
13CCCC C4 Therapeutics Inc7.2M+0.0%$33M2.0%
14KYTX Kyverna Therapeutics Inc2.9M−7.2%$26M1.5%
15ANNX Annexon Inc4.4M−14.9%$25M1.5%
16RPID Rapid Micro Biosystems Inc8.4M+0.0%$15M0.9%
17IRON Disc Medicine Inc141,234+0.0%$10M0.6%
18AVIR Atea Pharmaceuticals Inc2.1M−12.1%$10M0.6%
19XLO Xilio Therapeutics Inc664,021+0.0%$6M0.4%
20UPB Upstream Bio Inc600,949−30.7%$4M0.2%
21NAMS Newamsterdam Pharma Company99,999+0.0%$2M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.